Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Viridian Therapeutics has scored an FDA
WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its…
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to…
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient…
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
